Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

S1827

SAFC

Sodium deoxycholate

Pharma Manufacturing

Synonym(s):

3α,12α-Dihydroxy-5β-cholanic acid sodium salt, 7-Deoxycholic acid sodium salt, Desoxycholic acid sodium salt

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C24H39NaO4
CAS Number:
302-95-4
Molecular Weight:
414.55
Beilstein:
3581950
EC Number:
206-132-7
MDL number:
MFCD00064139
UNSPSC Code:
12161900
NACRES:
NA.21

biological source

animal

Quality Level

400

Assay

≥98% (HPLC)

form

powder

mol wt

micellar avg mol wt 1200-5000

aggregation number

3-12

CMC

2-6 mM (20-25°C)

HLB

16

suitability

suitable for manufacturing use

SMILES string

[Na+].[H][C@]12CC[C@@]3([H])[C@]4([H])CC[C@H]([C@H](C)CCC([O-])=O)[C@@]4(C)[C@@H](O)C[C@]3([H])[C@@]1(C)CC[C@@H](O)C2

InChI

1S/C24H40O4.Na/c1-14(4-9-22(27)28)18-7-8-19-17-6-5-15-12-16(25)10-11-23(15,2)20(17)13-21(26)24(18,19)3;/h14-21,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15-,16-,17+,18-,19+,20+,21+,23+,24-;/m1./s1

InChI key

FHHPUSMSKHSNKW-SMOYURAASA-M

Looking for similar products? Visit Product Comparison Guide

General description

Our SAFC® portfolio of high-quality raw materials for use in biopharmaceutical processing withstands strict quality control procedures plus the documentation and expertise to help our customers meet requirements as defined by the M-Clarity Program.

M-Clarity Program

Our comprehensive portfolio of upstream process chemicals not only provides biopharmaceutical manufacturers with high-quality raw materials for production of classical and novel therapies, but also helps them get to market faster and simplify regulatory challenges. Trust us to deliver supply chain transparency and reliable sourcing around the globe, streamlining your product qualification with best-in-class regulatory support and service.

Legal Information

SAFC is a registered trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

L L Liu et al.
Oncogene, 33(24), 3140-3150 (2013-07-16)
Prostate tumors develop resistance to androgen deprivation therapy (ADT) by multiple mechanisms, one of which is to express constitutively active androgen receptor (AR) splice variants lacking the ligand-binding domain. AR splice variant 7 (AR-V7, also termed AR3) is the most
Ayako Suzuki et al.
Nucleic acids research, 42(22), 13557-13572 (2014-11-08)
Here we conducted an integrative multi-omics analysis to understand how cancers harbor various types of aberrations at the genomic, epigenomic and transcriptional levels. In order to elucidate biological relevance of the aberrations and their mutual relations, we performed whole-genome sequencing
Jamie A Greig et al.
PLoS pathogens, 11(1), e1004630-e1004630 (2015-01-27)
The opportunistic human fungal pathogen, Candida albicans, undergoes morphological and transcriptional adaptation in the switch from commensalism to pathogenicity. Although previous gene-knockout studies have identified many factors involved in this transformation, it remains unclear how these factors are regulated to
Jelke J Fros et al.
The Journal of general virology, 96(Pt 3), 580-589 (2014-11-15)
The unfolded protein response (UPR) is a cellular defence mechanism against high concentrations of misfolded protein in the endoplasmic reticulum (ER). In the presence of misfolded proteins, ER-transmembrane proteins PERK and IRE1α become activated. PERK phosphorylates eIF2α leading to a
Matias Knuuttila et al.
The American journal of pathology, 184(8), 2163-2173 (2014-06-21)
Androgens are key factors involved in the development and progression of prostate cancer (PCa), and PCa growth can be suppressed by androgen deprivation therapy. In a considerable proportion of men receiving androgen deprivation therapy, however, PCa progresses to castration-resistant PCa
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service